Every dose figure attached to Dihexa comes from preclinical rodent work, not from clinical practice. The published animal studies used injected and oral delivery and reported active amounts in the microgram to low single-digit milligram per kilogram range, and the compound holds no FDA approval and has no controlled human trial behind it. Numbers circulating outside that literature are extrapolations rather than findings, and the distance between a rodent protocol and a human dose is where the real exposure sits.
Every published Dihexa dose figure comes from rodent studies and is reported in micrograms to low single-digit milligrams per kilogram of body weight, with no controlled human trial establishing a safe or effective dose in people.
Rodent pharmacology reaches for whichever route answers the question in front of it, and for this compound that meant three: intraperitoneal injection, oral gavage, and intravenous injection. The oral results carried the most weight in the research program, because peptides are ordinarily digested before absorption, and reported activity after gavage was the evidence offered that the analog had been stabilized against enzymatic breakdown. The routes absent from the record matter as much as the ones inside it.
The published animal record for this compound covers intraperitoneal, intravenous, oral gavage, and local intramuscular delivery, and contains no data supporting subcutaneous, intranasal, sublingual, or transdermal administration.
Animal doses are reported per kilogram of body weight because exposure scales with body size, and a flat milligram figure would mean something entirely different in a twenty-gram mouse than in a three-hundred-gram rat. Read on that scale, the published amounts are strikingly small. A minimum effective dose in this literature identifies the smallest amount that moved one endpoint in one rodent model, which is not a therapeutic dose and says nothing about what amount would be appropriate in a person.
In the published rodent literature, injected doses that moved cognitive endpoints are reported in the microgram-per-kilogram range and oral doses in a higher band sitting at or below roughly the low single-digit milligrams per kilogram.
Preparation is the unglamorous half of a dose figure, and it decides whether the number means anything at all. The molecule is a small peptide carrying lipophilic modifications meant to improve membrane crossing, which complicates getting it into aqueous solution and pushes laboratories toward vehicles that can carry a compound of mixed character. Purity carries the same weight, since a dose figure only holds if the material contains what the label claims at the stated concentration, and research-grade supply chains do not carry the identity, purity, sterility, and endotoxin testing a pharmaceutical product must pass.
A vehicle-only control group receiving the identical preparation minus the active compound is what allows a laboratory study to separate the compound's effect from the carrier's.
The published protocols cluster around once-daily administration across a defined treatment block rather than continuous infusion or intermittent cycling, with the window chosen to fit the behavioral assay rather than to model chronic therapy. Two designs sit inside that record and answer different questions, and treating them as interchangeable is a common source of overstatement.
| Design feature | Acute dosing studies | Repeated daily dosing studies |
|---|---|---|
| Typical window | Administration around the time of testing | Several days to a few weeks |
| Timing relative to the deficit | Given in relation to the amnestic challenge | Begun after the injury or lesion |
| Question answered | Immediate functional effect | Accumulating change across a treatment block |
| Durability evidence | Not addressed | Thin, with few observations past the dosing period |
Reported animal protocols use once-daily dosing across blocks running from several days to a few weeks, and the public record contains no long-duration continuous dosing study capable of showing tolerance or cumulative organ effects.
The pharmacokinetics are the reason the doses look the way they do. Angiotensin IV, the parent peptide in this research line, is degraded by peptidases almost immediately, and the analog was built by adding modifications at the ends of the backbone to shield it from those enzymes and raise lipophilicity enough to cross membranes including the blood-brain barrier.
No published human pharmacokinetic dataset exists for this compound, and rodent absorption, protein binding, enzyme complement, and clearance routinely differ from human handling, so no animal dose can be translated into a human one on measured evidence.
Converting an animal dose into a human one looks like arithmetic and is not, which is where a great deal of harm in this space begins. Regulatory practice does not scale by body weight at all; it scales by body surface area, correcting for the far higher metabolic rate per unit of mass in small animals, and that correction typically shrinks the equivalent human figure well below a naive weight-based multiplication. A second layer of uncertainty sits on top for this compound, since the rodent findings come from artificial models such as chemically induced amnesia and experimental injury, and success in those models has historically been a weak predictor of benefit in human neurological disease.
Regulatory practice scales an animal dose by body surface area rather than body weight, and treats the resulting human equivalent dose only as the starting point for a monitored phase one escalation study, never as a usable dose.
No, and that single fact governs everything else in this topic. There is no published, peer-reviewed, controlled human trial establishing a safe dose, an effective dose, a dosing interval, or an upper limit, and the compound carries no marketing approval from the United States Food and Drug Administration or comparable regulators elsewhere. An empty record is not reassurance, because absence of reported harm in a setting where nobody is systematically looking for harm is an absence of information rather than a safety finding.
No published, peer-reviewed, controlled human clinical trial has established a safe dose, an effective dose, a dosing interval, or an upper limit for this compound, and it holds no marketing approval from the FDA or comparable regulators.
A dosing range in legitimate drug development is bounded from above by toxicology, and that ceiling does not exist here. The short rodent efficacy studies generally noted no obvious gross adverse effects inside their brief windows, which is not a safety clearance, since a two-week behavioral study is not built to detect organ toxicity, tumor promotion, immune effects, or slow-developing harm. Material of uncertain provenance adds impurity, incorrect-concentration, and mislabeling risks that exist regardless of what the molecule itself does.
The public record contains no repeat-dose toxicology, genotoxicity, or carcinogenicity package for this compound, and the paper tying its procognitive effects to hepatocyte growth factor receptor activation was retracted in 2025 after an institutional investigation found falsified or fabricated material.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
